EVIDENCE-BASED THERAPY TO REDUCE LIFE-THREATENING CARDIOVASCULAR EVENTS

Company Overview

NASDAQ: AMRN

AMARIN

APRIL 2026

Forward Looking Statements & Disclaimer

This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA® (icosapent ethyl) (VAZKEPA® in Europe and in other territories), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, generic product launches, research and development, intellectual property and litigation matters, and other statements and beliefs that are forward-looking in nature and depend upon or refer to future events or conditions, including certain financial initiatives, metrics, guidance, and other statements. These statements involve known and unknown risks, uncertainties and other factors that can cause actual results to differ materially. Investors should not place undue reliance on forward-looking statements, which speak only as of the presentation date of this presentation.

Please refer to the "Risk Factors" section in Amarin's most recent Forms 10-K and 10-Q filed with the SEC and cautionary statements outlined in recent press releases for more complete descriptions of risks in an investment in Amarin.

THIS PRESENTATION IS INTENDED FOR COMMUNICATION WITH INVESTORS AND NOT FOR DRUG PROMOTION.

A Message from our President & CEO

Aaron Berg, President & CEO

"We are creating a **new version of Amarin** – focused, leaner, and both financially and operationally stronger.

Our Q1 2026 results reflect the early, measurable progress generated by our **refined global business model,** which we implemented in mid-2025.

We are expanding the global market for VASCEPA® / VAZKEPA® (icosapent ethyl) through our **fully partnered international commercial strategy.** We have designed this approach to be our **growth engine, and the early results are encouraging.**

At the same time, we maintained our **U.S. leading market share** for VASCEPA, reflecting growing branded prescriptions and supportive updates to clinical data. Our streamlined domestic operations are an efficient, cash generating platform.

We have substantially completed our global restructuring resulting in a materially lower fixed cost structure. We were **cash flow positive for the second consecutive quarter in Q1 2026** and expect to generate positive cash flow for full year 2026. Our cash position increased and we have a debt free balance sheet."

Who We Are: An Established Leader in Cardiovascular Therapeutics

- **First and only FDA-approved** oral therapy to reduce cardiovascular (CV) risk when added to recommended statin therapy.
- 2018 groundbreaking clinical study[1] proved that VASCEPA (icosapent ethyl) **lowers the chance of a life-threatening CV event** (such as a heart attack or stroke) by **25%**[2] when added to a statin.[3]
- **Expanding evidence base continues to support IPE's role in CV risk reduction**, with continued recognition from medical societies worldwide and recent inclusion in the 2026 ACC/AHA/Multisociety Dyslipidemia Guideline[4], **reinforcing IPE's relevance** for millions living with persistent cardiovascular risk.

$3.5B
CUMULATIVE SALES SINCE LAUNCH IN 2013

30M+
PRESCRIPTIONS WRITTEN SINCE LAUNCH IN 2013

>260K
PRESCRIBERS

25%
RELATIVE RISK REDUCTION FOR CV EVENTS ON TOP OF STATIN THERAPY[3]

50+
COUNTRIES WITH CVRR APPROVALS[5]

CVRR = Cardiovascular Risk Reduction

70+
MEDICAL SOCIETY RECOGNITION GLOBALLY [5,6]

500+
SCIENTIFIC PUBLICATIONS VALIDATING THE SCIENCE

1. REDUCE-IT® study *N Engl J Med.* 2019; 380 (1): 11-22.
2. In adults on maximally tolerated statins with TG≥ 150 mg/dL and established CVD or diabetes and ≥ 2 CVD risk factors.
3. In a clinical study, patients treated with VASCEPA and a statin had fewer cardiovascular (CV) events (17.2%) compared to those who took a placebo (22%).
4. Blumenthal RS, Morris PB, Gaudino M, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. *J Am Coll Cardiol.* 2026 Mar 13:S0735-1097(25)10254-4. doi: 10.1016/j.jacc.2025.11.016. Epub ahead of print.
5. Data on File
6. Miller M, Tokgozoglu L, Parhofer KG, et al. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements. *Expert Rev Cardiovasc Ther.* 2022;20(8):609-625

Data as of 3/31/2026

Where We Stand: Leveraging a Global Footprint, Refined Strategy and Solid Financial Position; Poised for Long-Term Growth

- **Transformed international commercial strategy;** fully partnered and covering close to 100 countries; emphasis on Europe (Intellectual Property protection through 2039).
- **Restructuring initiatives substantially completed**.
- **Strong established partnerships globally,** with multiple long-duration revenue streams.
- **Large and growing global Total Addressable Markets,** ~ 640 M people living with cardiovascular disease (CVD).
- **VASCEPA/VAZKEPA (icosapent ethyl)**:
  - U.S.: leading share of IPE* prescriptions, 5 years post generic entry; source of continued revenue and cash flow.
  - International: 7 partnerships well-positioned to maximize global patient access.
- **Growing cash position**.
- **Executing on new and more efficient operating strategy to drive shareholder value**.

DUBLIN, IRELAND
(IRELAND TAX DOMICILE)

HQ: **BRIDGEWATER**, NJ

$308 M

CASH

20+ M

ADR SHARES OUTSTANDING

$0

DEBT

$1 BN

NOLs

Q1 2026

CASH FLOW POSITIVE
(expect to generate positive cash flow for FY 2026)

* IPE = Icosapent Ethyl

Financial data as of 3/31/2026

Our Financials: Executing a More Efficient Operating Model to Support Future Global Growth

Key Takeaways:

- ☑ Q1 2026 net revenue rose to $45.1 M
- ☑ Higher total revenue and lower total OPEX led to significantly narrowed losses
- ☑ On-track to achieve the ~$70 M of OPEX savings by the end of Q2 2026
- ☑ Cash flow positive; expect to generate positive cash flow for FY 2026
- ☑ $308 M in aggregate cash and investments; no long-term debt

Operating Results:

($ in M)	Q1 26	Q1 25	Change
Net Revenue	**45.1**	**42.0**	**7%**
U.S. Product NR	35.6	35.7	(0)%
Europe Product NR	4.9*	5.4	(9)%
RoW Product NR	2.8	--	NM
Licensing & Royalty	1.8	1.0	84%
Gross Profit	**17.8**	**25.1**	**(29)%**
% margin (Product NR)	*37%*	*59%*	*NM*
Operating Expenses	**(29.1)**	**(41.9)**	**(31)%**
SG&A	(21.1)	(36.6)	(42)%
R&D	(4.7)	(5.3)	(12)%
Restructuring	(3.3)	--	NM
Operating Loss	**(11.3)**	**(16.8)**	**(32)%**
% margin	*(25)%*	*(40)%*	*NM*
Net Loss	**(10.5)**	**(15.7)**	**(33)%**
% margin	*(23)%*	*(37)%*	*NM*

NM - Not Meaningful
** The slight decline in European revenue was attributable to moving to a partnered sales model in the second half of 2025*

Financial data as of 3/31/2026

Our U.S. Business: Implemented and Successfully Executing Refined Commercial Strategy to Maintain Profitable Branded Business

- **Proven efficacy in CVRR has built a large and durable U.S. market presence**.
- **Executing on a refined commercial strategy** focused on payer coverage post-loss of exclusivity, providing efficient revenue and positive cash flow.
- VASCEPA remains the clear **U.S. market leader** across all available icosapent ethyl products.
- VASCEPA-branded prescriptions rose by 17% in Q1 2026 from Q1 2025.
- **Expect continued efficient cash generation** through sustaining branded sales.
- Proven **complement to other cardiometabolic therapies**.

Our International Business: Maximizing Ex-U.S. Access Through a Syndicate of Established Partners

Vascepa® (icosapent ethyl) Vazkepa® (icosapent ethyl)



Our International Business: Recordati Partnership Key To Maximize VAZKEPA Opportunity in Europe

- June 2025: **exclusive, long-term license and supply agreement**; 15-year initial term, auto renewal in 2039.
- Recordati licensed to **commercialize VAZKEPA in 59 countries**, primarily Europe.
- **Favorable economics**:
  - Upfront cash payment of $25 M.
  - Supply-based revenues.
  - Royalties for the supply of the product.
  - Future milestone payments totaling up to $150 M; first milestone contingent upon Recordati achieving annual net sales of $100 M.

RECORDATI

COMPANY HIGHLIGHTS

- Large product portfolio.
- Long CV disease heritage.
- Presence in 150+ countries, including all of Europe.
- Fully-integrated operations – R&D, commercialization and licensing.

Accelerates Amarin's global efficiencies and fortifies capital structure

- Cost effective revenue generation and expense optimization.
- Optimized inventory management to align with revenue growth in early-stage markets.
- Strengthened cash position.

Our International Business: Seven Partners Actively Building Market Opportunities Across Multiple Continents

7 Ex-U.S. partnerships focused on maximizing patient access to VASCEPA/ VAZKEPA – many in early commercialization stages, poised for future growth.



Regulatory:

- Monitoring regulatory reviews of previously submitted applications in **Thailand and the Philippines**.
- On track to submit a new filing **in Malaysia** in Q2 2026.
- **Additional markets** with regulatory submissions pending review.

Pricing & Reimbursement:

- Various P&R processes ongoing across the partnerships.

Commercialization:

- Preparing for early 2027 launches in **South Korea and Singapore**.
- **Commercializing across 11 countries**.
- **Realized increased year-over-year demand** in all launched markets.
- Partnerships providing **growing cash generation**.

CMC = Chemistry, Manufacturing & Controls
HEOR = Health Economics & Outcomes Research

Improving Market Dynamics: Regulatory Label Changes, Updated Guidelines & Amplified Disease Awareness of Elevated Triglycerides/FCS

Fibrate Label Change

June 2025 - **FDA updated the labelling requirements for fenofibrates** to highlight that these medications are **not associated with any proven cardiovascular (CV) benefits**.

Significant opportunity globally.

U.S. : 11 M prescriptions / ~2 M patients, 60% of which are combined with a statin.

Western Europe: over 2 M patients being treated with fibrates.

IPE in 2026 ACC/AHA/Multisociety Dyslipidemia Guideline

Icosapent ethyl (IPE) is recognized to reduce CV event risk in combination with statin therapy in individuals at high risk of CVD with persistent TG; this is consistent with guidance from other CV societies, including the **2025 ESC/EAS Dyslipidemias Guideline** focused update.

This guideline also states that there is no reduction in CV events when fenofibrate is added to statin therapy in primary prevention patients with diabetes.

Amplified Disease Awareness

Innovation in the triglyceride space is advancing awareness of the risks in patients with elevated triglycerides, **a net positive for the category and VASCEPA globally.**

With these premium-priced emerging therapies, payers have and will continue to enforce **step-edit requirements** for prescribers through existing, proven products such as VASCEPA.

These market dynamics focused on patients with elevated triglycerides continue to support VASCEPA, a widely accessible, safe, and cost-effective oral option approved in the U.S. for sHTG, as well as approved in over 50 markets globally for CVRR.

Note: Market data as of 12/12/25.

2026 Focus: Continued Execution & Driving Long-term Growth Opportunities

A **multi-pronged** and **multi-national** approach:

- **Expand** therapeutic reach across all partnered international markets.
- **Maintain** IPE leadership in the U.S.
- **Realize** the full operational improvements from global restructuring initiatives.
- **Invest** prudently to enhance understanding and awareness of IPE.
- **Work** actively with exclusive financial advisor to identify value-building strategic opportunities.

Amarin Key Takeaways

HEALTHY FINANCIALS

Cash Flow

EXPECT TO BE CASH FLOW POSITIVE FOR FULL YEAR 2026

$308M

CASH*

$0

DEBT*

UNTAPPED POTENTIAL

~640M

PEOPLE LIVING WITH CVD, MAKING IT THE LEADING CAUSE OF DEATH WORLDWIDE[1]

7

PARTNERSHIPS ACROSS THE GLOBE

2039

EUROPEAN IP RUNWAY

PRODUCT POWER

>260K

PRESCRIBERS

30M+

PRESCRIPTIONS WRITTEN SINCE 2013 LAUNCH

$3.5B

CUMULATIVE SALES SINCE 2013 LAUNCH

STRONG SCIENCE

3

SUCCESSFUL PHASE 3 PIVOTAL TRIALS

25%

RELATIVE RISK REDUCTION ON TOP OF STATIN THERAPY[4]

1ST

AND ONLY FDA-APPROVED ORAL AGENT TO REDUCE CV RISK WHEN ADDED ON TOP OF RECOMMENDED STATIN THERAPY

MEDICAL ENDORSEMENT

500+

SCIENTIFIC PUBLICATIONS VALIDATING THE SCIENCE

70+

MEDICAL SOCIETY RECOGNITIONS GLOBALLY[2,3]

50+

COUNTRIES WITH CVRR[5] APPROVALS[3]

* Financials as of 3/31/26

Notes: Market data as of March 2026. 1.https://www.bhf.org.uk/-/media/files/for-professionals/research/heart-statistics/bhf-cvd-statistics-global-factsheet.pdf, 2. Miller M, Tokgozoglu L, Parhofer KG, et al. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements. *Expert Rev Cardiovasc Ther.* 2022;20(8):609-625, 3.Data on File 4. Bhatt DL, et al; for REDUCE-IT Investigators. N Engl J Med. 2019;380(1):11-22; Bhatt DL, et al. Presented at: American Heart Association Scientific Sessions; November 10-12, 2018; Chicago, IL, 5. CVRR = Cardiovascular Risk Reduction